Form 4: Teva Grants EVP Lippman 27,347 RSUs Under 10b5-1 Plan

Teva Pharmaceutical Industries Ltd. granted its EVP of Business Development, Evan Lippman, 27,347 restricted share units as part of a Rule 10b5-1 plan.

Summary

• Evan Lippman, Executive Vice President of Business Development at Teva Pharmaceutical Industries Ltd., was granted 27,347 Restricted Share Units (RSUs).
• The grant date for these RSUs was March 4, 2026.
• Each RSU represents a contingent right to receive one ordinary share or its cash equivalent at settlement, at the discretion of the Human Resources and Compensation Committee.
• The RSUs will vest in four annual installments: 6,836 units on March 4, 2027; 6,836 units on March 4, 2028; 6,836 units on March 4, 2029; and 6,839 units on March 4, 2030.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices designed to align management incentives with long-term company performance and retention.

Positives

• The RSU grant aligns the executive's long-term interests with those of shareholders, incentivizing sustained performance.
• The vesting schedule provides a strong retention incentive for a key executive over a four-year period.

Negatives

• The grant of RSUs, while common, represents potential future dilution for existing shareholders when the shares are issued upon vesting.

Future Outlook

The filing details a future vesting schedule for the granted Restricted Share Units, with installments occurring annually from March 2027 through March 2030, indicating a long-term incentive structure for the executive.

Industry Context

StockSavvy.ai notes that the grant of Restricted Share Units (RSUs) is a standard practice in the pharmaceutical industry for executive compensation, aiming to retain key talent and align management incentives with long-term shareholder value creation. This type of equity award is common among large pharmaceutical companies like Pfizer, Merck, and Johnson & Johnson, which frequently use multi-year vesting schedules to encourage sustained performance and commitment.

Comparison to Industry Standards

• The use of Restricted Share Units (RSUs) with a multi-year vesting schedule is a common and accepted practice for executive compensation across the global pharmaceutical industry, comparable to practices at companies such as Novartis, AstraZeneca, and GlaxoSmithKline.
• The specific number of units granted to an EVP of Business Development would typically be benchmarked against peer companies of similar size and market capitalization, considering the executive's role and performance, though specific comparative data is not provided in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential minor dilution upon vesting of RSUs, but also benefit from enhanced executive alignment with long-term company performance.
• Employees: The RSU grant to a senior executive can signal stability in leadership and a commitment to long-term incentives within the company.

Next Steps

• 6,836 Restricted Share Units are scheduled to vest on March 4, 2027.
• 6,836 Restricted Share Units are scheduled to vest on March 4, 2028.
• 6,836 Restricted Share Units are scheduled to vest on March 4, 2029.
• 6,839 Restricted Share Units are scheduled to vest on March 4, 2030.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Restricted Share Units, RSU Grant, Executive Compensation, Insider Transaction, Form 4, Evan Lippman, 10b5-1 Plan